Terry Jr & Callahan (2020) and Tregellas & Wylie (2019) have extensively reviewed the α7 nAChR agonists that have been tested in the treatment of cognition disturbances in schizophrenia [173,176]. This evidence concerns the gene CHRNA7 and schizophrenia.